Bluebird bio details plans to file three blockbusters
Biotech looks to take on Novartis, Gilead, and Juno in CAR-T
Cancer/ Market Access/ News/ News/ News/ Oncology
Richard Staines
blood cancer, bluebird bird, cancer, Gilead, Juno, Novartis
0 Comment
Biotech looks to take on Novartis, Gilead, and Juno in CAR-T
Richard Staines
cancer, CAR T, Cellectis, Gilead, Juno, Novartis, R&D, safety
0 Comment
Regulator agrees to restart phase 1 trial of UCART 123
News/ News/ Oncology/ R&D/ Top stories
Richard Staines
blood cancer, CAR T, Gilead, Juno, Novartis
0 Comment
Juno has hopes pinned on JCAR017
Richard Staines
blood cancer, cancer, CAR T, Juno, Kite Pharma, non-Hodgkin lymphoma, Novartis
0 Comment
Biotech plans pivotal trial next year.
Richard Staines
blood cancer, bluebirdbio, cancer, CAR T, Juno, Kite Pharma, Novartis
0 Comment
Kite to start filing data for KTE-C19 with US regulator.
Richard Staines
cancer, cancer immunotherapy, Juno, Kite Pharma, Novartis, R&D, safety
0 Comment
Doubts over Juno CAR-T therapy after two more trial deaths.
Richard Staines
Adaptimmune, cancer, immuno-oncology, Juno, Kite, T-cell
0 Comment
T-cell trial will include controversial chemo agent fludarabine.
Articles/ Cancer/ R&D/ Views and analysis
Richard Staines
cancer, Cancer Research Technology, CAR T, immunotherapy, Juno, Kite, Novartis, Oncology
0 Comment
Novartis may have concerns about commercial prospects, says expert.